MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fonc.2025.1688779

Медицинская библиотека · Frontiers in oncology · 2025

Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohort.

Glienke Maximilian, Himmelsbach Ruth, Zirngibl Max, Metzger Patrick, Kühn Julia, Miething Cornelius, Sigle August, Gratzke Christian, Nientiedt Cathleen, Rassner Michael, Becker Heiko, Duyster Justus, Lassmann Silke, Werner Martin, Börries Melanie, Grabbert Markus

СтатьяПеревод в очереди

Аннотация

OBJECTIVES

Molecular tumor boards (MTBs) have become an integral component of precision oncology, yet data on their real-world impact in urologic cancers are limited. This study aimed to characterize the molecular landscape of urologic malignancies presented to the MTB at the University Medical Center Freiburg and to evaluate the frequency and clinical relevance of genomic alterations across tumor entities.

METHODS

We retrospectively analyzed 118 patients with histologically confirmed urologic tumors presented at the Freiburg MTB between Januar 2019 and December 2024. Comprehensive molecular profiling was performed using next-generation sequencing (TruSight Oncology 500 or whole exome sequencing). Data were analyzed for mutation frequency, tumor mutational burden (TMB), and co-occurrence patterns, and integrated with clinical data to guide therapy recommendations.

RESULTS

Somatic mutations were identified in 90.6% of cases. Frequent alterations included TP53, BRCA2, KMT2D, and ATM, with DNA damage response and chromatin remodeling pathways commonly affected. Prostate cancers showed high rates of BRCA2 and APC co-mutations, indicating potential benefit from combined PARP and Wnt-targeted therapies. In bladder and upper tract urothelial carcinomas (UTUC), KMT2C co-occurred with genes such as SPTA1 and LRP1B, suggesting a hypermutated, immunoresponsive phenotype. Renal tumors frequently harbored alterations in VHL, PBRM1, and SETD2. Rare entities such as penile and testicular tumors displayed distinct mutation patterns, including BRCA1/2 and MMR gene alterations.

CONCLUSIONS

Comprehensive molecular profiling in a MTB setting reveals distinct and therapeutically relevant mutational patterns across urologic cancers. These data support the integration of MTBs into clinical workflows and highlight the potential of co-mutational signatures to guide personalized treatment strategies.

Для цитирования: Glienke Maximilian, Himmelsbach Ruth, Zirngibl Max, Metzger Patrick, Kühn Julia, Miething Cornelius, Sigle August, Gratzke Christian, Nientiedt Cathleen, Rassner Michael, Becker Heiko, Duyster Justus, Lassmann Silke, Werner Martin, Börries Melanie, Grabbert Markus. Comprehensive molecular profiling of urologic tumors presented in a molecular tumor board: insights from a real-world precision oncology cohort.. Frontiers in oncology. 2025. DOI: 10.3389/fonc.2025.1688779.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.